Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | FER | P16591 | 1/20 | 0.53 |
| ▸ | LTK | P29376 | 1/20 | 0.53 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indirubin SCHEMBL31032717 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL30215500 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL9899338 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL20535353 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL29361016 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL27678 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL3857676 | 0.98 | MAOA (0.62) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL21067723 | 0.93 | MAOA (0.56) | MAOAMAOBLRRK2PDGFRAFER | |
| SCHEMBL22300581 | 0.87 | MAOA (0.50) | MAOAMAOBLRRK2PDGFRAFER | |
| SCHEMBL21440382 | 0.86 | MAOA (0.49) | MAOAMAOBLRRK2PDGFRAFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | claimed |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2015-03-26 | — | — | US | claimed |
| EP-0987027-B1 | Ethyl acetate extract from Indigo plant | HAYASHIBARA BIOCHEM LAB (JP) | 2004-08-11 | — | — | EP | claimed |
| US-6524625-B2 | Soaking raw indigo plant in organic solvent containing ethyl acetate-soluble ingredient (kaempferol); extract useful as antiseptic, viricide, antitumor agent, apoptosis-/cytokine production- controlling agent, enzyme inhibitors | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUTO (JP) | 2003-02-25 | — | — | US | claimed |
| US-20020068094-A1 | PHYSIOLOGICALLY ACTIVE EXRACT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2002-06-06 | — | — | US | claimed |
| EP-0987027-A1 | Physiologically active extract | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2000-03-22 | — | — | EP | claimed |
| EP-4674839-A1 | NOVEL INDOLINE DERIVATIVE AND USE THEREOF | CK Regeon Inc. (KR) | 2026-01-07 | — | — | EP | disclosed |
| US-12516022-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2024181799-A1 | NOVEL INDOLINE DERIVATIVE AND USE THEREOF | 주식회사 씨케이리제온 | 2024-09-06 | — | — | WO | disclosed |
| US-20240182416-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240010635-A1 | NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF | Pelemed Co., Ltd. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4253385-A1 | NOVEL INDIRUBIN DERIVATIVE HAVING HETEROBICYCLIC RESIDUE AND USE THEREOF | Pelemed Co., Ltd. (KR) | 2023-10-04 | — | — | EP | disclosed |
| US-20070155816-A1 | CDK(Cyclin-dependent kinase) inhibitor; cancer, apoptosis; 5-NH-trimethyl-indirubin-3-oxime | ANYGEN CO., LTD. (KR) | 2007-07-05 | — | — | US | disclosed |
| EP-0987027-B1 | Ethyl acetate extract from Indigo plant | HAYASHIBARA BIOCHEM LAB (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-20040072790-A1 | Safe natural pharmaceutical composition for treating cancer | LIU YAGUANG (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040072790-A1 | Safe natural pharmaceutical composition for treating cancer | LIU YAGUANG (US) | 2004-04-15 | — | — | US | disclosed |
| US-6524625-B2 | Soaking raw indigo plant in organic solvent containing ethyl acetate-soluble ingredient (kaempferol); extract useful as antiseptic, viricide, antitumor agent, apoptosis-/cytokine production- controlling agent, enzyme inhibitors | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUTO (JP) | 2003-02-25 | — | — | US | disclosed |
| US-20020068094-A1 | PHYSIOLOGICALLY ACTIVE EXRACT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2002-06-06 | — | — | US | disclosed |
| EP-0987027-A1 | Physiologically active extract | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | MAOA 414/4885MAOB 318/4885LRRK2 872/4885 |
| US-20020068094-A1 | PHYSIOLOGICALLY ACTIVE EXRACT | SI, TYR, COMT | MAOA 83/4885MAOB 58/4885LRRK2 2044/4885 |
| US-20040072790-A1 | Safe natural pharmaceutical composition for treating cancer | MATR3, HPN, HAMP | MAOA 1249/4885MAOB 1993/4885LRRK2 3531/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | MAOA 698/4885MAOB 573/4885LRRK2 1497/4885 |
| US-20240010635-A1 | NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF | FLT3, RET, FER | MAOA 2977/4885MAOB 1138/4885LRRK2 181/4885 |
| US-20240182416-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AHR, ARNT, NR4A1 | MAOA 414/4885MAOB 318/4885LRRK2 872/4885 |
| US-20070155816-A1 | CDK(Cyclin-dependent kinase) inhibitor; cancer, apoptosis; 5-NH-trimethyl-indirubin-3-oxime | CDK7, CDKL5, CDK3 | MAOA 2666/4885MAOB 1645/4885LRRK2 1862/4885 |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | CYP7A1, CYP3A7, UGT2B7 | MAOA 217/4885MAOB 173/4885LRRK2 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.